Indwelling central venous access port insertion during bevacizumab-based therapy

Area of Science:

• Oncology
• Vascular Biology

Background:

• Indwelling central venous catheters and implantable ports are crucial for cancer patient care.
• Bevacizumab, an anti-VEGF antibody, improves survival in metastatic colorectal cancer and other malignancies.
• Bevacizumab's side effects, like bleeding and impaired wound healing, raise concerns for surgical procedures.

Purpose of the Study:

• To assess the periprocedural morbidity associated with indwelling central venous access port insertion in patients receiving bevacizumab.
• To evaluate the safety of central venous access port placement shortly before or during bevacizumab therapy.

Main Methods:

• Retrospective analysis of 57 cancer patients who received central venous access ports.
• Patients either were on bevacizumab treatment or received it within 4 weeks prior to port insertion.
• Focused on periprocedural complications, including wound healing, bleeding, infection, and skin ulceration.

Main Results:

• No cases of delayed wound healing, abnormal bleeding, wound infection, or skin ulceration were observed.
• These findings were consistent across all patients, including those with diabetes mellitus.
• The study involved patients with various cancer types.

Conclusions:

• Central venous access port insertion appears safe when performed shortly before or during bevacizumab treatment.
• The data suggest that bevacizumab does not significantly increase periprocedural morbidity related to port placement.
• Further research with larger cohorts is warranted to confirm these preliminary findings.